Medtronic Freestyle Aortic Root Bioprosthesis: Implant Techniques

Doty, Donald B.; Cafferty, A; Kon, Neal D.; Huysmans, Hans A.; Krause, Albert H.; Westaby, Stephen

doi:10.1111/j.1540-8191.1998.tb01099.x

Cited by 27 publications

(22 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The bioprosthesis can be implanted as a subcoronary valve replacement, as a complete aortic root replacement, or as a root inclusion. 4 Previously published reports confirm excellent hemodynamic performance associated with stentless aortic valves. [5][6][7] However, clinical outcomes, late durability, mode, and mechanism of valve failure during long-term follow-up remain to be elucidated.…”

mentioning

confidence: 57%

See 1 more Smart Citation

Long-Term Clinical and Echocardiographic Follow-Up of the Freestyle Stentless Aortic Bioprosthesis

et al. 2012

View full text Add to dashboard Cite

Background-Stentless aortic bioprostheses were designed to provide enhanced hemodynamic performance and potentially greater longevity. The present report describes the outcomes of patients with the Freestyle stentless bioprosthesis followed for Յ18 years. Methods and Results-Between 1993 and 2011, 430 patients underwent primary aortic valve replacement with a Freestyle bioprosthesis in the subcoronary position. Mean age was 68.2Ϯ8.2 years. All of the clinical and echocardiographic data were collected prospectively. Mean overall follow-up was 9.1Ϯ4.4 years and was complete in all of the patients. In-hospital mortality was 3.5% (nϭ15). Overall, 10-and 15-year survival were 60.7% and 35.0%, respectively. Fifty-one patients required reoperation during follow-up, including 27 for structural valve deterioration (SVD). Overall, freedom from reoperation was 91.0% and 75.0% at 10 and 15 years, whereas freedom from reoperation for SVD was 95.9% and 82.3%, respectively. At 10 and 15 years, freedom from reoperation for SVD was 94.0% and 62.6% for patients Ͻ60 years of age and 96.3% and 88.4% for patients Ն60 years of age (Pϭ0.002). The median time to explant for SVD was 10.7 years. SVD presented mostly as acute, severe aortic insufficiency attributed to leaflet tear (77.8%).The independent risk factors for reoperation for SVD were age Ͻ60 years (Pϭ0.001) and dyslipidemia (Pϭ0.02). Conclusions-Aortic valve replacement with the Freestyle bioprosthesis in a subcoronary position provides good long-term clinical and echocardiographic outcomes for patients Ͼ60 years of age. Severe aortic insufficiency with leaflet tear is the major mode of SVD leading to reoperation in these patients. (Circulation. 2012;126[suppl 1]:S198 -S204.)

show abstract

mentioning

confidence: 57%

“…The operative technique has been described previously. 4 The noncoronary sinus of Valsalva was preserved. Sizing is performed with the sizer provided for the FBS valve, with consideration given to the size at both the annulus and sinotubular ridge.…”

Section: Study Populationmentioning

confidence: 99%

Long-Term Clinical and Echocardiographic Follow-Up of the Freestyle Stentless Aortic Bioprosthesis

et al. 2012

View full text Add to dashboard Cite

show abstract

“…Fourteen studies reported follow-up greater than 36 months (range, 37 to 92 months) [10,12,16,18,21,22,24,25,27,30,31,[33][34][35]. Five studies had follow-up less than 3 years (range, 6 to 24 months) [14,20,23,28,36], and the remaining studies did not report length of follow-up [9,11,13,17,19,26,29,32].…”

Section: Quantity Of Studiesmentioning

confidence: 98%

“…All of the included studies were retrospective observational studies except one prospective series [16]. Fourteen studies had more than 100 patients (range, 101 to 317 patients) [10,11,13,18,21,22,24,25,27,29,31,32,34,35], including two multicenter registries [10,32], and the remaining series had fewer than 100 patients (range, 10 to 80 patients) [9, 12, 14-17, 19, 20, 23, 26, 28, 30, 33, 36].…”

Section: Quantity Of Studiesmentioning

confidence: 99%

“…The Bentall procedure was performed with a Freestyle stentless aortic root bioprosthesis (Medtronic Inc, Minneapolis, MN) in 12 series [10,11,13,14,16,17,21,22,29,32,33,36], with different hand-sewn composite grafts in 8 series [9,12,18,23,[25][26][27]35], with BioValsalva conduit (Vascutek Terumo, Renfrewshire, UK) in 5 series [9,19,20,28,34], with Shelhigh BioConduit model NR-2000C (Shelhigh, Inc, Milburn, NJ) or No-React BioConduit (BioIntegral Surgical, Inc, Mississauga, Ontario, Canada) in 3 series [15,30,31], with Prima Plus aortic root bioprosthesis (Edwards Lifesciences, Irvine, CA) in 3 series [11,17,29], and with Toronto root bioprosthesis (St. Jude Medical, St. Paul, MN) in 3 series [22,24,29].…”

Section: Operative Datamentioning

confidence: 99%

See 1 more Smart Citation

Aortic Root Replacement With Biological Valved Conduits

Castrovinci

Tian

Murana

et al. 2015

The Annals of Thoracic Surgery

View full text Add to dashboard Cite

Recent Advances in the Modification and Improvement of Bioprosthetic Heart Valves

Tong,

Cai,

Wang

et al. 2024

Small

View full text Add to dashboard Cite

Valvular heart disease (VHD) has become a burden and a growing public health problem in humans, causing significant morbidity and mortality worldwide. An increasing number of patients with severe VHD need to undergo heart valve replacement surgery, and artificial heart valves are in high demand. However, allogeneic valves from donors are lacking and cannot meet clinical practice needs. A mechanical heart valve can activate the coagulation pathway after contact with blood after implantation in the cardiovascular system, leading to thrombosis. Therefore, bioprosthetic heart valves (BHVs) are still a promising way to solve this problem. However, there are still challenges in the use of BHVs. For example, their longevity is still unsatisfactory due to the defects, such as thrombosis, structural valve degeneration, calcification, insufficient re‐endothelialization, and the inflammatory response. Therefore, strategies and methods are needed to effectively improve the biocompatibility and longevity of BHVs. This review describes the recent research advances in BHVs and strategies to improve their biocompatibility and longevity.

show abstract

Medtronic Freestyle Aortic Root Bioprosthesis: Implant Techniques

Abstract: The Medtronic Freestyle bioprosthesis is an effective and versatile device for replacement of the aortic valve. It offers implant techniques that can treat the aortic root pathology encountered at surgery and allows the operation to proceed according to surgeon preference.

Cited by 27 publications

References 14 publications

Long-Term Clinical and Echocardiographic Follow-Up of the Freestyle Stentless Aortic Bioprosthesis

Long-Term Clinical and Echocardiographic Follow-Up of the Freestyle Stentless Aortic Bioprosthesis

Aortic Root Replacement With Biological Valved Conduits

Recent Advances in the Modification and Improvement of Bioprosthetic Heart Valves

Contact Info

Product

Resources

About